Correlation Between Radiomic Features Based on Contrast-enhanced Computed Tomography Images and Ki-67 Proliferation Index in Lung Cancer: A Preliminary Study
Overview
Pulmonary Medicine
Authors
Affiliations
Background: The purpose of the study was to investigate the association between radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lung cancer.
Methods: One hundred and ten patients with lung cancer confirmed by surgical histology were retrospectively included. Radiomic features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features serving as image predictors of Ki-67 status in lung cancer and to investigate the relationship between these features and Ki-67 PI.
Results: Higher Ki-67 expression was more common in men (P = 0.02) and patients with a smoking history (P = 0.01). Twelve radiomic features were significantly associated with Ki-67 status. Multivariate logistic regression analysis identified inverse variance, minor axis, and elongation as independent predictors of Ki-67 PI. There was a positive correlation between inverse variance, minor axis, elongation (P = 0.00, P = 0.02, and P = 0.14, respectively) and Ki-67 PI. The area under the curve to identify high Ki-67 status for inverse variance was 0.77 with a cutoff value of 0.47, which was significantly higher than for minor axis and elongation (P = 0.02 and P = 0.03, respectively).
Conclusion: Radiomic features based on contrast CT images, including inverse variance, minor axis, and elongation, can serve as noninvasive predictors of Ki-67 status in patients with lung cancer. Inverse variance could be superior to the other radiomic features to identify high Ki-67 status.
Evaluation of radiomic feature harmonization techniques for benign and malignant pulmonary nodules.
Huchthausen C, Shi M, de Sousa G, Colen J, Shelley E, Larner J ArXiv. 2025; .
PMID: 39876938 PMC: 11774441.
Luo X, Zheng R, Zhang J, He J, Luo W, Jiang Z Front Oncol. 2024; 14:1329801.
PMID: 38384802 PMC: 10879429. DOI: 10.3389/fonc.2024.1329801.
Hu D, Li X, Lin C, Wu Y, Jiang H Diagnostics (Basel). 2023; 13(19).
PMID: 37835850 PMC: 10573026. DOI: 10.3390/diagnostics13193107.
Liu F, Li Q, Xiang Z, Li X, Li F, Huang Y Front Oncol. 2023; 13:1175010.
PMID: 37706180 PMC: 10497212. DOI: 10.3389/fonc.2023.1175010.
Sun H, Zhou P, Chen G, Dai Z, Song P, Yao J J Cancer Res Clin Oncol. 2023; 149(11):9301-9315.
PMID: 37204513 DOI: 10.1007/s00432-023-04856-2.